First, the growth rate of performance in the first quarter of 20021is less than 50%;
Second, the performance in the first quarter of 20021may drop sharply. Judging from the pre-increase in performance in the first quarter of 2020 (about 45% to 65% year-on-year), the performance in the first quarter of this year may be less than expected, no matter from which aspect! As a result, the organization began to kill and flee collectively on April 7.
Zhejiang Huahai Pharmaceutical Co., Ltd., founded in 1989, is a pharmaceutical enterprise integrating pharmaceutical preparations and raw materials. Its predecessor was Linhai Hongqiao Synthetic Chemical Plant, and it was changed to Zhejiang Huahai Pharmaceutical Co., Ltd. in June 20001year. It was listed on the Shanghai Stock Exchange in 2003. The company has a registered capital of 780 million yuan, total assets of 4.5 billion yuan, and covers an area of 65.438+200,000 square meters. It has 654.38+05 branches (subsidiaries) in the United States, Shanghai, Jiangsu, Hangzhou and other places with more than 4,000 employees. From 2000 to 2008, it was ranked among the "Top Ten Enterprises in Zhejiang Pharmaceutical Industry" for nine consecutive years. The company is mainly engaged in the research, development, production and sales of generic drugs, biological drugs, innovative drugs and characteristic APIs. The company's antihypertensive drugs are mainly pulverization and sartan, and it is the world's leading manufacturer of pulverization and sartan. The main products are paroxetine mesylate capsules, doxycycline sustained-release tablets, losartan potassium tablets, paroxetine hydrochloride tablets, donepezil tablets, ropinirole tablets, lamotrigine sustained-release tablets and bupropion sustained-release tablets.
Licensed items: pharmaceutical production; Drug import and export; Drug wholesale; Health food production; Health food sales (projects subject to approval according to law can only be carried out after approval by relevant departments, and the specific business projects are subject to the approval results). General projects: technical services, technical development, technical consultation, technical exchange, technology transfer and technology popularization (except for projects that need to be approved according to law, business activities shall be independently carried out according to law with business licenses).